Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based ...

Pfizer said on Friday it had filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

The lawsuit says Novo Nordisk’s offer for drug startup Metsera isn’t reasonably likely to be completed.

Pfizer has decided to sue Metsera and Novo over $8.5B bid, citing antitrust risks and asserting regulatory advantage.

Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...

Novo Nordisk, a leader in weight-loss drugs, is offering $6 billion up front with the potential for later milestone payments ...

(Reuters) -Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk, accusing them of breaking a merger agreement ...

President Donald Trump has received updated flu and COVID-19 booster shots in preparation for upcoming travel, the president’s physician announced Oct. 10. Sean P. Barbabella, a U.S. Navy captain, ...